Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity
Jens Dannull(University of St.Gallen), Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gabi Hanna(University of North Carolina at Chapel Hill), Diem-Thu Lesher(Duke Medical Center), Wen‐Ning Qi, Robert A. Holzknecht(Durham VA Medical Center), Hilliard F. Seigler(Duke University), Douglas S. Tyler(University of North Carolina at Chapel Hill)
Cited by 59
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors
|Cancer Research|2012|458
The landscape of the mesenchymal signature in brain tumours
|Brain|2019|389
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208